779 related articles for article (PubMed ID: 19559476)
21. Chemotherapy for second-stage human African trypanosomiasis.
Lutje V; Seixas J; Kennedy A
Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD006201. PubMed ID: 23807762
[TBL] [Abstract][Full Text] [Related]
22. Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series.
Checchi F; Piola P; Ayikoru H; Thomas F; Legros D; Priotto G
PLoS Negl Trop Dis; 2007 Nov; 1(2):e64. PubMed ID: 18060083
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes.
Balasegaram M; Young H; Chappuis F; Priotto G; Raguenaud ME; Checchi F
Trans R Soc Trop Med Hyg; 2009 Mar; 103(3):280-90. PubMed ID: 18947846
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness.
Milord F; Pépin J; Loko L; Ethier L; Mpia B
Lancet; 1992 Sep; 340(8820):652-5. PubMed ID: 1355219
[TBL] [Abstract][Full Text] [Related]
25. Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness.
Jansson-Löfmark R; Na-Bangchang K; Björkman S; Doua F; Ashton M
Antimicrob Agents Chemother; 2015 Feb; 59(2):1299-307. PubMed ID: 25512417
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial.
Burri C; Nkunku S; Merolle A; Smith T; Blum J; Brun R
Lancet; 2000 Apr; 355(9213):1419-25. PubMed ID: 10791526
[TBL] [Abstract][Full Text] [Related]
27. [A trial treatment with eflornithine of trypanosomiasis caused by Trypanosoma brucei gambiense in the Peoples Republic of the Congo].
Eozenou P; Jannin J; Ngampo S; Carme B; Tell GP; Schechter PJ
Med Trop (Mars); 1989; 49(2):149-54. PubMed ID: 2507863
[TBL] [Abstract][Full Text] [Related]
28. [Treatment of sleeping disease caused by trypanosoma brucei gambiense with alpha-difluoromethylornithine (DFMO) in a rural hospital in Zaire].
De Groof D; Bruneel H; Musumari TS; Ruppol JF
Med Trop (Mars); 1992; 52(4):369-75. PubMed ID: 1494306
[TBL] [Abstract][Full Text] [Related]
29. Drug resistance in human African trypanosomiasis.
Barrett MP; Vincent IM; Burchmore RJ; Kazibwe AJ; Matovu E
Future Microbiol; 2011 Sep; 6(9):1037-47. PubMed ID: 21958143
[TBL] [Abstract][Full Text] [Related]
30. Eflornithine for the treatment of human African trypanosomiasis.
Burri C; Brun R
Parasitol Res; 2003 Jun; 90 Supp 1():S49-52. PubMed ID: 12811548
[TBL] [Abstract][Full Text] [Related]
31. The treatment of human African trypanosomiasis.
Pépin J; Milord F
Adv Parasitol; 1994; 33():1-47. PubMed ID: 8122565
[No Abstract] [Full Text] [Related]
32. Treatment of human African trypanosomiasis--present situation and needs for research and development.
Legros D; Ollivier G; Gastellu-Etchegorry M; Paquet C; Burri C; Jannin J; Büscher P
Lancet Infect Dis; 2002 Jul; 2(7):437-40. PubMed ID: 12127356
[TBL] [Abstract][Full Text] [Related]
33. Melarsoprol-free drug combinations for second-stage Gambian sleeping sickness: the way to go.
Chappuis F
Clin Infect Dis; 2007 Dec; 45(11):1443-5. PubMed ID: 17990226
[No Abstract] [Full Text] [Related]
34. Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo.
Balasegaram M; Harris S; Checchi F; Hamel C; Karunakara U
Bull World Health Organ; 2006 Oct; 84(10):777-82. PubMed ID: 17128357
[TBL] [Abstract][Full Text] [Related]
35. The evolving spectrum of human African trypanosomiasis.
Kennedy PGE
QJM; 2024 Jun; 117(6):391-395. PubMed ID: 38065835
[TBL] [Abstract][Full Text] [Related]
36. African sleeping sickness.
Hedley L; Fink D; Sparkes D; Chiodini PL
Br J Hosp Med (Lond); 2016 Oct; 77(10):C157-C160. PubMed ID: 27723399
[No Abstract] [Full Text] [Related]
37. Treatment options for second-stage gambiense human African trypanosomiasis.
Eperon G; Balasegaram M; Potet J; Mowbray C; Valverde O; Chappuis F
Expert Rev Anti Infect Ther; 2014 Nov; 12(11):1407-17. PubMed ID: 25204360
[TBL] [Abstract][Full Text] [Related]
38. An open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central Zaire.
Pepin J; Milord F; Mpia B; Meurice F; Ethier L; DeGroof D; Bruneel H
Trans R Soc Trop Med Hyg; 1989; 83(4):514-7. PubMed ID: 2694491
[TBL] [Abstract][Full Text] [Related]
39. Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model.
Dauchy FA; Bonhivers M; Landrein N; Dacheux D; Courtois P; Lauruol F; Daulouède S; Vincendeau P; Robinson DR
PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005125. PubMed ID: 27855164
[TBL] [Abstract][Full Text] [Related]
40. Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo.
Balasegaram M; Harris S; Checchi F; Ghorashian S; Hamel C; Karunakara U
Bull World Health Organ; 2006 Oct; 84(10):783-91. PubMed ID: 17128358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
